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Abstract (79 words; guideline 150) 24 
 25 
Efficacies of ceftazidime-avibactam (4:1 w/w) and ceftazidime were tested against ceftazidime-26 
susceptible (blaKPC-2-negative), and meropenem- and ceftazidime-resistant (blaKPC-2-positive), 27 
Klebsiella pneumoniae in a 52-hour, multiple-dose, abdominal abscess model in the rat.  28 
Efficacies corresponded to minimum inhibitory concentrations (MICs) measured in vitro and 29 
were consistent with drug exposures modelled from pharmacokinetics in infected animals.  The 30 
ceftazidime, ceftazidime-avibactam, and meropenem control treatments were effective in the rat 31 
abscess model against the susceptible strain, whereas only ceftazidime-avibactam was effective 32 
against K. pneumoniae harboring blaKPC-2.  33 
 34 
Text (2441 words not including Abstract, References, Acknowledgement, Geographic 35 
location, Declaration of Interest, or Tables and Figures: guideline maximum 9000) 36 
 37 
Introduction 38 
 39 
Avibactam is a new inhibitor RIVHULQHȕ-lactamases that is approved in the USA (1) and Europe 40 
(2) for therapeutic use in combination with ceftazidime.  Avibactam displays a broader spectrum 41 
of inhibition than the previously approved E-lactamase inhibitors, clavulanic acid, sulbactam, 42 
and tazobactam: a key property being its inhibition of Klebsiella pneumoniae carbapenemase 43 
(KPC) YDULDQWȕ-lactamases (3±7).  This inhibition translated to efficacy against KPC-producing 44 
K. pneumoniae in acute lethal septicemia and neutropenic mouse thigh and intraperitoneal 45 
infection models (8, 9).  One of the target indications for ceftazidime-avibactam is complicated 46 
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intra-abdominal infection (1, 2, 10), which can include intraperitoneal abscesses (11).  Therefore, 47 
we have examined the efficacy of ceftazidime-avibactam against K. pneumoniae, with or without 48 
blaKPC-2, in fecal pellets implanted in the rat abdomen as a model of carbapenem-resistant intra-49 
abdominal abscess infection.   50 
 51 
Some of the results of this study have been presented in conference form (Sleger T, Krause KM, 52 
Slee AM, Nichols WW. Efficacy of ceftazidime-avibactam in the rat intra-abdominal abscess 53 
model against a meropenem-resistant isolate of Klebsiella pneumoniae carrying blaKPC-2.  [#B-54 
070], Interscience Conference of Antimicrobial Agents and Chemotherapy  San Diego, USA.  55 
September 17±21, 2015.). 56 
 57 
Methods 58 
 59 
Two bacterial strains were used in the efficacy studies: ceftazidime- and meropenem-susceptible 60 
K. pneumoniae KB KPC-6 (blaKPC-2-negative) and ceftazidime- and meropenem-resistant K. 61 
pneumoniae 283KB7 (blaKPC-2-positive), both from the culture collection of Cerexa Inc 62 
(Oakland, USA).  Carriage or non-carriage of blaKPC-2 was determined by use of Check-Points 63 
microarray kits (Check-Points Health BV, Wageningen, The Netherlands) as described 64 
previously (12).  Carriage of extended VSHFWUXPȕ-lactamase genes was not noted in either strain. 65 
Minimum inhibitory concentrations (MICs) were determined by broth microdilution with the 66 
concentration of avibactam fixed at 4 mg/L while the concentration of ceftazidime was varied in 67 
two-fold increments (13, 14). 68 
 69 
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Infection and dose-response experiments were performed at ViviSource (now Avastus), 70 
Cambridge, MA, USA, under the standards set by its Institution Animal Care and Use 71 
Committee (IACUC), consistent with those of the Office of Laboratory Animal Welfare 72 
(OLAW), National Institutes of Health, USA.  Anesthesia was achieved in animals by oral 73 
dosing with Tramadol (4 mg/kg) prior to surgery, and again 24 h after completing surgery.  For 74 
the abdominal abscess model, bacteria were mixed with sterilized rat feces and molten agar to 75 
form plugs of approximate volume 0.5 mL that were surgically implanted (1 per animal; 76 
approximately 1 x 105 colony-forming units [CFU]/plug) under anesthesia into the abdominal 77 
cavities of male Sprague-Dawley rats that weighed 180±225 g.    In untreated animals, over the 78 
course of 52 h, the plugs developed into distinct, yellow-white encapsulated structures that could 79 
be removed intact for analysis.  In animals that underwent effective treatment, those abscess-like 80 
structures were absent, leaving smaller lesions that could still be dissected out and processed.  81 
Each rat was treated at 4, 12, 20, 28, and 36 h after bacterial challenge with one of a range of 82 
doses of ceftazidime (8, 16, 32, or 64 mg/kg subcutaneous, sc), ceftazidime-avibactam (8:2, 16:4, 83 
32:8, or 64:16 mg/kg, i.e. 4:1 w/w, sc), or meropenem (40 mg/kg intravenous, iv) as control for 84 
expression of carbapenem-resistance in vivo.  The specified dose was identical at each time 85 
point.  The dose regimens were intended to elicit a measurable range of bacterial responses, not 86 
to mimic human exposures.  The group size for each dose regimen was 10 animals. At 52 h post-87 
challenge, animals were euthanized, abscesses removed and weighed, and viable bacteria 88 
counted by homogenization, serial dilution, and plating on tryptic soy agar. 89 
 90 
Bacterial count data were summarized graphically using box-and-whisker plots, displaying the 91 
median and inter-quartile range of the counts for each dose group. Whiskers contained all data 92 
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points that fell within 1.5 times the interquartile range above and below the upper and lower 93 
quartile, respectively, with any outliers falling outside that range shown as individual points.  No 94 
subculturing to test for the possible development of resistance was performed. 95 
 96 
Pharmacokinetics (PK) of ceftazidime and avibactam were measured via single sc doses of 97 
ceftazidime-avibactam of, respectively, 8 + 2 or 64 + 16 mg/kg (based on weight of parent drug) 98 
in groups of four satellite animals subjected to agar plug infections as above with K. pneumoniae 99 
27-908M (blaTEM-1, blaSHV-27, blaKPC-2) using a validated liquid chromatography/mass 100 
spectrometry/mass spectrometry (LC-MS/MS) method (15). Preparation of satellite infected rats 101 
and dosing and sampling were performed at NeoSome Life Sciences, Lexington, MA, USA, to 102 
OLAW standards under WKH FRPSDQ\¶V ,$&8& SROLFLHV DQG JXLGHOLQHV.  For implanting 103 
inoculated agar plugs, rats were anesthetized to surgical depth by isoflurane inhalation confirmed 104 
by toe-pinch. A single dose of each combination was given at 12 h following surgery and 105 
implantation.  Blood samples ( ȝL) were taken from the saphenous vein directly into 106 
K2EDTA collection tubes at times 0.08, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, and 6 h after dosing. A 107 
pre-dose sample was also taken.  Plasma was separated by centrifugation, decanted and stored at 108 
±80°C until assay.   109 
 110 
Drug concentrations were determined by liquid chromatography/mass spectrometry/mass 111 
spectrometry (LC-MS/MS), detailed methods for which have been described in a separate 112 
validation study (15).  %ULHIO\ȝ/VDPSOHVRIUDWSODVPDSODVPDZHUHGLVSHQVHGLQWR-well 113 
SODWHV IROORZHG E\  ȝ/ of protein precipitation solution (100 mM ammonium formate, pH 114 
9.0, and acetonitrile; 5:95 by volume) containing internal standards (NXL-105 for avibactam and 115 
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cefdinir for ceftazidime). Plates were vortexed for 2 min and then centrifuged at 2150 × g for 5 116 
PLQDW&&OHDUVXSHUQDWDQWVROXWLRQVȝ/ZHUHWUDQVIHUUHGWRFOHDQSODWHVDQGGULHGWR117 
FRPSOHWHQHVVXQGHUQLWURJHQ6DPSOHVZHUHUHGLVVROYHG LQZDWHU ȝ/VKDNHQ IRUPLQ118 
and then transferred to the autosampler of a Shimadzu liquid chromatography system (Shimadzu 119 
Corporation, Japan).  Chromatographic separation of ceftazidime, avibactam and their respective 120 
LQWHUQDOVWDQGDUGVZDVDFKLHYHGE\LQMHFWLQJVDPSOHVRIȝ/RQDQ$&(&-$5ȝPî121 
4.6 mm) column (MAC-MOD Analytical, Chadds Ford, PA, USA) maintained at room 122 
temperature.  The constitution and periods of application of various mixtures of aqueous formic 123 
acid (0.1% v/v) and acetonitrile mobile phases are described in full in (15) so are not repeated 124 
here.  A post-column infusion flow of methanol (0.8 ml/min) was introduced to increase the 125 
electrospray performance.  Retention times were as follows: avibactam and NXL105 internal 126 
standard, 1.25 and 1.06 min, respectively; ceftazidime and cefdinier internal standard, 1.84 and 127 
1.95 min, respectively.  Mass spectrometry was performed using an AB Sciex 6500 Triple 128 
quadrupole mass spectrometer (AB Sciex, Foster City, CA, USA) operated in electrospray 129 
ionization mode.  Data were acquired and analysed using Analyst software (v 1.6.2).  As above, 130 
the mass spectrometer parameters were described in detail in (15) and so are not repeated here. 131 
 132 
Rat plasma protein binding was assumed to be 14% for ceftazidime (16), and 2.1% for avibactam 133 
(unpublished report, Novexel). Drug exposures, as % of time that unbound compounds exceeded 134 
specified concentrations, were calculated with reference to the 52-h period from the initiation of 135 
infection to the time at which abscesses were recovered.  This 52-h basis was used because, 136 
although the inter-dose periods were regular (8 h), there was a 4-h period before dosing started, 137 
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and a post-final-dose period of 16 h before efficacy was assessed. Therefore, exposures could not 138 
be expressed as percent values of an inter-dose period. 139 
 140 
Results and Discussion 141 
 142 
Table 1 displays MICs and the corresponding median log(CFU/g abscess) recovered after 143 
treatment with the highest repeat doses of ceftazidime (64 mg/kg) or ceftazidime-avibactam 144 
(64:16 mg/kg), or the 40 mg/kg repeat dose of meropenem. The efficacies were consistent with 145 
expectations based on MICs. Thus, all three treatments were efficacious against the model 146 
abscesses containing the blaKPC-2-negative strain of K. pneumoniae, which was susceptible to 147 
ceftazidime, ceftazidime-avibactam and meropenem with MICs 4, 0.12, and 0.06 mg/L 148 
respectively (median bacterial recovery from 3.3±3.9 logCFU/g abscess: reduced compared with 149 
the vehicle control level of 8.8 logCFU/g).  However, only the ceftazidime-avibactam treatment 150 
was similarly efficacious against the blaKPC-2-containing K. pneumoniae, against which the MIC 151 
of ceftazidime-avibactam was 2 mg/L and the median bacterial recovery was near the lower limit 152 
of detection at 3.3 logCFU/g. The ceftazidime MIC of >128 mg/L and the meropenem MIC of 32 153 
mg/L against this strain were associated with lack of efficacy against the model abscesses 154 
(median bacterial recovery of 9.3 logCFU/g for both treatments). It should be noted that the 155 
doses of ceftazidime were identical between ceftazidime monotherapy and ceftazidime-156 
avibactam, with avibactam being dosed at one-quarter that of ceftazidime by weight, as used in 157 
other efficacy studies (8, 17) and in the clinical formulation (1, 2).  The meropenem treatment 158 
served as a control to demonstrate that the possession of blaKPC-2 was associated not only with an 159 
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elevated MIC of the carbapenem in vitro but that the carbapenem resistance was also expressed 160 
in the animal infection model. 161 
 162 
Figure 1 provides graphical plots of the bacterial recovery data for all treatments.  Results for 163 
intra-abdominal abscesses containing the blaKPC-2-negative K. pneumoniae are shown in Figure 164 
1A. As expected, abscesses recovered from rats dosed with vehicle yielded about 109 CFU/g 165 
abscess (median 8.8 logCFU/g, Table 1). All four ceftazidime-avibactam treatments were fully 166 
efficacious, as was the single regimen of meropenem in control animals, with bacterial 167 
recoveries near the lower limit of detection (~103 CFU/g abscess). The higher doses of 168 
ceftazidime of 64 and 32 mg/kg/dose were also efficacious, but efficacy was reduced for the 169 
ceftazidime-alone doses of 16 and 8 mg/kg. Growth of the blaKPC-2-positive strain of K. 170 
pneumoniae in abscesses in control rats dosed with vehicle also reached about 109 CFU/g 171 
abscess (median 9.5 logCFU/g, Table 1) over the period of the study (Figure 1B). All the 172 
ceftazidime (and the meropenem control) treatments were ineffective against this strain in the 173 
model, with bacterial growth being similar to that seen in the abscesses from control animals 174 
treated with vehicle (Figure 1B).  The effect of meropenem could thus be related qualitatively to 175 
the MICs measured in vitro and the result demonstrated that the molecular mechanism of 176 
meropenem resistance was expressed in this in vivo infection model. A dose-response 177 
relationship was observed for the different ceftazidime-avibactam treatments against the 178 
blaKPC-2-positive strain, 283KB7, yielding between 1-log and 6-log reduction in CFU/g abscess 179 
compared with abscesses from rats treated with vehicle or ceftazidime monotherapy (Figure 1B). 180 
 181 
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Based on the above results, the efficacy of ceftazidime-avibactam against K. pneumoniae 182 
harboring blaKPC-2 demonstrated that distally-dosed avibactam penetrated into the abdominal 183 
DEVFHVVHVDQGLQKLELWHGWKHȕ-lactamase there sufficiently for ceftazidime to be bactericidal (12) 184 
at that site. This is consistent with the efficacy of ceftazidime-avibactam in complicated intra-185 
abdominal infections (cIAI) that has been reported from phase 2 and phase 3 clinical trials, 186 
although noting that organisms harboring blaKPC were not reported from the great majority of 187 
patients in those trials (10, 18±20).   188 
 189 
As stated in the Methods, the range of ceftazidime and ceftazidime-avibactam doses was chosen 190 
to elicit efficacy responses that would demonstrate the effect of avibactam in reversing blaKPC-2-191 
associated ceftazidime-resistance in an in vivo abscess model.  The ceftazidime-susceptible 192 
isolate was included as control to confirm that in vitro susceptibility to ceftazidime was 193 
associated with ceftazidime efficacy in the model.  This study was not designed to elucidate the 194 
pharmacodynamics of the ceftazidime-avibactam combination.   However such 195 
pharmacodynamic studies have been performed; and the results were consistent with the 196 
antibacterial effect of ceftazidime-avibactam being related to the times that ceftazidime and 197 
avibactam exceeded critical concentrations (21, 22).  From this time-dependency, one would 198 
predict that more frequent dosing would have resulted in greater efficacy of the lower doses of 199 
ceftazidime-avibactam against the K. pneumoniae strain harbouring KPC-2 in the current 200 
abdominal abscess model.  Although this frequency-of-dosing prediction was not tested, the 201 
ceftazidime and avibactam exposures, measured as times above their respective critical 202 
concentrations, were consistent with the observed efficacies, as follows. 203 
 204 
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The efficacies of ceftazidime and ceftazidime-avibactam described here were compared with 205 
predicted drug exposures calculated from PK models derived from plasma concentration±time 206 
courses determined in satellite infected rats. The derived parameters used for the model-based 207 
calculations are provided in Table 2. The index of exposure related to the efficacy of ceftazidime 208 
is %fT>MIC (2123) which is the percent of time that the ceftazidime concentration in plasma 209 
exceeds the MIC measured against the infecting bacterium in vitro. The index that has been used 210 
to relate avibactam exposure to restoration of the antibacterial activity of ceftazidime has been 211 
time above a threshold concentration: %fT>CT (21, 22, ±24). Threshold concentrations of 0.5 and 212 
1 mg/L have been identified as useful measures for relating avibactam exposures to restoration of 213 
ceftazidime activity and were therefore also modeled here. Table 3 shows the modeled free 214 
plasma exposures as percentages of the time of duration of the infection. 215 
 216 
With respect to the blaKPC-2-negative K. pneumoniae KB KPC-6, ceftazidime alone was fully 217 
efficacious at 64 and 32 mg/kg (Table 1, Figure 1), which corresponded with calculated fT>MIC 218 
4 mg/L of 42.8% and 35.3% (Table 3). The two lower doses of ceftazidime alone yielded 219 
intermediate efficacies (Figure 1) and corresponded to lower calculated fT>MIC 4 mg/L of 220 
27.9% and 20.2%.  The in vitro MIC of ceftazidime with avibactam against this blaKPC-2-negative 221 
strain was lower, being 0.12 mg/L. As a result, when ceftazidime was combined with avibactam 222 
(4:1 w/w), the lower doses of 16 and 8 mg/kg were also fully efficacious in that bacterial counts 223 
in the abscesses were reduced to near the limit of detection (Figure 1). These lower ceftazidime 224 
doses corresponded to values of fT>MIC 0.12 mg/L calculated from the PK model of 65.2% and 225 
58.0% (Table 3). Clearly, the increased potency of ceftazidime in the presence of avibactam 226 
against this strain (measured as a decrease in the in vitro MIC on the addition of avibactam) 227 
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translated to an increased efficacy of the 16 and 8 mg/kg doses in vivo (Figure 1). The 228 
corresponding modeled exposures of avibactam were 11.5% and 8.3% fT>0.5 mg/L (5.4% and 229 
0% fT>1 mg/L) (Table 3). 230 
 231 
In the case of the blaKPC-2-positive K. pneumoniae, lack of efficacy at all ceftazidime doses 232 
(Figure 1) corresponded to calculated 0% fT>MIC of >128 mg/L (Table 3). In contrast, with co-233 
administered avibactam at 16 mg/kg/dose, which yielded a calculated fT>0.5 mg/L of 24.0% 234 
(18.8% fT>1 mg/L), the 64 mg/kg dose of ceftazidime, calculated to yield 50.2% fT>MIC 2 235 
mg/L (i.e. the MIC of ceftazidime-avibactam), corresponded with maximum efficacy (Table 3, 236 
Figure 1). Intermediate efficacies against the blaKPC-2-positive strain corresponded to calculated 237 
ceftazidime exposures of 42.8, 35.3, and 27.9% fT>MIC of 2 mg/L combined with respective 238 
calculated avibactam exposures of 15.4, 11.5, and 8.3% fT> CT 0.5 mg/L (10.1, 5.4, and 0% 239 
fT>CT 1 mg/L) (Table 3). 240 
 241 
The above modelled drug exposures are consistent with efficacy in this abdominal abscess model 242 
being achieved at an avibactam exposure somewhat lower than the 50% fT>CT of 1 mg/L value 243 
that has been used as pharmacokinetic/pharmacodynamic (PK/PD) target in dose assessments 244 
(2324). That is, the avibactam PK/PD target used in dose assessments appears to have been 245 
conservative relative to the calculated exposure that corresponded to bactericidal efficacy in this 246 
rat abscess model against a ceftazidime- and meropenem-resistant isolate of K. pneumoniae 247 
harboring blaKPC-2. 248 
 249 
 250 
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 251 
 252 
 253 
 254 
Geolocation 255 
 256 
The efficacy experiments were performed in Cambridge, MA, USA. Dosing and sampling for 257 
measurements of plasma concentrations of ceftazidime and avibactam in satellite infected rats 258 
were performed in Lexington, MA, USA. Bioanalysis of blood samples, and PK data analysis 259 
and modelling were performed in Waltham, MA, USA. Statistical analyses were performed in 260 
Sheffield, UK. 261 
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Efficacy of ceftazidime-avibactam in a rat intra-abdominal abscess model against a ceftazidime- and meropenem-resistant isolate of 363 
Klebsiella pneumoniae carrying blaKPC-2  364 
 365 
Tables and Figures 366 
 367 
Table 1.  Comparative efficacies of discriminatory doses of ceftazidime, ceftazidime-avibactam, 368 
and meropenem against K. pneumoniae KB KPC-6, not carrying, or 283KB7, carrying, blaKPC-2 369 
(ceftazidime- and meropenem-susceptible or -resistant, respectively) 370 
 371 
Treatment Dose 
(mg/kg/dose) 
K. pneumoniae  
(blaKPC-2-negative) 
K. pneumoniae  
(blaKPC-2-positive) 
MIC (mg/L) Median 
log(CFU/g)a 
MIC (mg/L) Median 
log(CFU/g)a 
Vehicle - - 8.8 - 9.5 
CAZ b 64 4 3.3 >128 9.3 
CAZ-AVI b 64:16 0.12c 3.4 2c 3.3 
MER b 40 0.06 3.9 32 9.3 
aLimit of detection 3.0 (i.e. 1 x 103 CFU/g abscess) 372 
bCAZ=ceftazidime; AVI=avibactam; MER=meropenem 373 
cAvibactam fixed at 4 mg/L for the MIC measurements 374 
 375 
 376 
 377 
 378 
 379 
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 380 
 381 
Table 2.  Estimated unbound compartmental PK parameters of ceftazidime and avibactam in infected rats  382 
Parameter Ceftazidime a Avibactam b 
No. of compartments 1 2 
Absorption rate constant, Ka (h-1)  0.90 1.56 
Clearance (L/h/kg)  0.33 2.16 
Volume (L/kg)  0.079 0.966 
Clearance2 (L/h/kg)  - 3.74 
Volume2  (L/kg)  - 0.40 
a
 Observed unbound non-compartmental parameters: Vz/F (L/kg) = 0.362, Cl/F (L/h/kg) = 0.336 and t½ (h) = 0.74 383 
b
 Observed unbound non-compartmental parameters: Vz/F (L/kg) = 2.33, Cl/F (L/h/kg) = 2.16 and t½ (h) = 0.73 384 
 385 
 386 
 387 
 388 
 389 
 390 
391 
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 392 
Table 3.  Ceftazidime and avibactam exposures calculated from pharmacokinetics in infected rats, 393 
expressed as fT>MIC or fT>CT (threshold concentration) of 0.5 and 1 mg/L 394 
Modeled 
dose (mg/kg) 
AVIa fT>CT 
of 0.5 mg/L 
AVI fT>CT 
of 1 mg/L 
K. pneumoniae  
(blaKPC-2-negative) 
K. pneumoniae  
(blaKPC-2-positive) 
MIC (mg/L) 
CAZa 
fT>MIC b 
MIC (mg/L) 
CAZ 
fT>MIC b 
CAZ (64) 0.0% c 0.0% c 4 42.8% c >128 d 0.0% c 
CAZ (32) 0.0% 0.0% 4 35.3% >128 0.0% 
CAZ (16) 0.0% 0.0% 4 27.9% >128 0.0% 
CAZ   (8) 0.0% 0.0% 4 20.2% >128 0.0% 
CAZ-AVI 
(64:16) 
24.0% 18.8% 0.12 80.2% 2 50.2% 
CAZ-AVI 
(32:8) 
15.4% 10.1% 0.12 72.7% 2 42.8% 
CAZ-AVI 
(16:4)  
11.5% 5.4% 0.12 65.2% 2 35.3% 
CAZ-AVI 8.3% 0.0% 0.12 58.0% 2 27.9% 
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(8:2) 
a
 AVI=avibactam; CAZ=ceftazidime 395 
b
 In the case of monotherapy, the ceftazidime fT>MIC was estimated as the time that the free plasma 396 
FRQFHQWUDWLRQRIFHIWD]LGLPHZDVWKH0,&RIFHIWD]LGLPH:KHQWKHWKHUDS\ZDVFHIWD]LGLPH-avibactam, 397 
the ceftazidime fT>MIC was estimated as the time that the free plasma concentration of ceftazidime wDV398 
the MIC of ceftazidime-avibactam. 399 
c
 Times are expressed as percent of the 52-hour period from the start of the infection to harvesting the 400 
abscesses 401 
d
 An MIC value of 256 mg/L was used for calculating ceftazidime fT>MIC of >128 mg/L 402 
 403 
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FIG 1.  Comparative efficacies of ceftazidime, ceftazidime-avibactam, and meropenem against (A) 404 
ceftazidime- and meropenem-susceptible, blaKPC-2-negative, K. pneumoniae KB KPC-6, and (B) 405 
ceftazidime- and meropenem-resistant, blaKPC-2-positive, K. pneumoniae 283KB7.   406 
AVI = avibactam; CAZ = ceftazidime.  Magnitudes per dose are shown: see the text for the times of 407 
dosing. 408 
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